Status: Recruiting
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
Participants needed: 78
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Heidelberg Pharma AGUpdated: Jul 24, 2024Locations: 16
Eligibility criteria
Male or female aged ≥18 years. [+7]
For patient entering the Phase 2a part only: Prior treatment with any approved o... [+12]